Get the Stockscreener App
53.32
6.36%
-3.62
After Hours:
53.32
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 12-Month HighShould You Buy? - MarketBeat
Jennison Associates LLC Has $138.43 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Janney Montgomery Scott LLC Sells 2,218 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by E. Ohman J or Asset Management AB - MarketBeat
Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals - TipRanks
Breakeven On The Horizon For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Yahoo Finance
BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74 -February 03, 2025 at 10:36 am EST - Marketscreener.com
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Exclusive Access: Tarsus Pharma's Double-Header at Elite Healthcare Investment Forums - StockTitan
How To Trade (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $62.00 Price Target at Barclays - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 9% After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 9% Higher After Analyst Upgrade - MarketBeat
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts - Benzinga
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $62.00 at Barclays - MarketBeat
Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potential - MSN
Tarsus Pharmaceuticals Inc (NASDAQ: TARS): An Enticing Stock To Watch - Stocks Register
Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal
Tarsus: Promising Investment, But Timing Is The Key (NASDAQ:TARS) - Seeking Alpha
Oppenheimer Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $72.00 - MarketBeat
First Week of TARS March 21st Options Trading - Nasdaq
Tarsus PharmaceuticalEye Care Therapeutics - MSN
Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair - MSN
Grant GrossMendelsohn LLC Sells 14,331 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Average Target Price from Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Publishes Corporate Presentation – Enhances Stakeholder InsightOn January 13, 2025, Tarsus Pharmaceuticals, Inc. shared its corporate presentation on its website’s Investor & News section, as detailed in the lates - Defense World
Tarsus Pharmaceuticals, Inc Announces Board and Committee Changes -January 17, 2025 at 05:09 pm EST - Marketscreener.com
Assenagon Asset Management S.A. Buys 5,565 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround - MSN
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 6.3%Time to Sell? - MarketBeat
Tarsus Pharmaceuticals is Now Oversold (TARS) - Nasdaq
Tarsus CEO Bobby Azamian: Clearing Crusty Eyelids with Xdemvy - Orange County Business Journal
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap DownTime to Sell? - MarketBeat
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY - WICZ
Tarsus Provides 2025 Update: Accelerating the Launch of - GlobeNewswire
Tarsus' XDEMVY Eye Treatment Hits $113M Sales, Plans New Rosacea Drug Development - StockTitan
Analysts Expect Breakeven For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Before Long - Simply Wall St
JPMorgan Chase & Co. Has $14.48 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
JPMorgan Chase & Co. Buys 420,057 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength? - Yahoo Finance
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):